AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schülin, T.
Right arrow Articles by Eliopoulos, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schülin, T.
Right arrow Articles by Eliopoulos, G. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1520-1523, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro

T. Schülin,1,2 C. B. Wennersten,1 M. J. Ferraro,2,3 R. C. Moellering Jr.,1,2 and G. M. Eliopoulos1,2,*

Department of Medicine, West Campus, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215,1 Harvard Medical School, Boston, Massachusetts 02115,2 and Massachusetts General Hospital, Boston, Massachusetts 021143

Received 17 November 1997/Returned for modification 26 February 1998/Accepted 1 April 1998

The in vitro activities of 13 antimicrobial agents against 30 strains of Legionella spp. were determined. Rifapentine, rifampin, and clarithromycin were the most potent agents (MICs at which 90% of isolates are inhibited [MIC90s], <= 0.008 µg/ml). The ketolide HMR 3647 and the fluoroquinolones levofloxacin and BAY 12-8039 (MIC90s, 0.03 to 0.06 µg/ml) were more active than erythromycin A or roxithromycin. The MIC90s of dalfopristin-quinupristin and linezolid were 0.5 and 8 µg/ml, respectively. Based on class characteristics and in vitro activities, several of these agents may have potential roles in the treatment of Legionella infections.

* Corresponding author. Mailing address: Department of Medicine---West Campus, Beth Israel Deaconess Medical Center, One Deaconess Rd., Boston, MA 02215. Phone: (617) 632-8586. Fax: (617) 632-7442. E-mail: geliopou{at}bidmc.harvard.edu.

Antimicrobial Agents and Chemotherapy, June 1998, p. 1520-1523, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.